<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01001663</url>
  </required_header>
  <id_info>
    <org_study_id>M-20090101</org_study_id>
    <nct_id>NCT01001663</nct_id>
  </id_info>
  <brief_title>Comparison of the FemoSeal® Arterial Closure Device to Manual Compression After Coronary Angiography</brief_title>
  <acronym>CLOSE-UP I</acronym>
  <official_title>Comparison of the FemoSeal® Arterial Closure Device to Manual Compression After Coronary Angiography: the CLOSE-UP I Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital Skejby</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vingmed Danmark A/S</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital Skejby</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Is the FemoSeal® closure device safer and more comfortable than manual compression for
      femoral artery access closure after coronary angiography?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Access site complication after coronary angiography is still a challenge in everyday
      practice. The FemoSeal® closure device has proven very safe as shown in the swedish SCAAR
      registry. This study is aimed to investigate, in a randomized design, if the FemoSeal® has an
      advantage in safety and efficacy over manual compression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of ipsilateral palpable groin hematomas with largest diameter exceeding 5 cm.</measure>
    <time_frame>20 minutes, 1 hour and at discharge, pooled</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of ipsilateral palpable groin hematomas with largest diameter exceeding 5 cm. Patient self-measurements.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of: major vascular complications necessitating surgical repair, A-V fistulation, pseudoaneurysm needing treatment, major bleeding needing transfusion and infection needing antibiotics .</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hemostasis, from sheath removal to hemostasis is achieved</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from end of closure procedure to ambulation. 1h bedrest recommended.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device deployment failure</measure>
    <time_frame>20 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to cessation of continuous minor oozing measured from the end of the closure procedure</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for repeated manual compression after end of the closure procedure</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain and discomfort measured on a numerical pain rating scale (0-10)</measure>
    <time_frame>20 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasovagal reaction (clinical signs AND Systolic BP drop of more than 30 mmHg AND/OR pulse drop more than 30 b/min. AND reversible immediately after treatment by atropin, fluids)</measure>
    <time_frame>20 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The patient seeking medical assistance for all-cause closure site related symptoms after discharge.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain and discomfort measured on a numerical pain rating scale (0-10)</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain and discomfort measured on a numerical pain rating scale (0-10)</measure>
    <time_frame>Discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain and discomfort measured on a numerical pain rating scale (0-10)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1005</enrollment>
  <condition>Coronary Angiography Via Femoral Artery Access</condition>
  <arm_group>
    <arm_group_label>FemoSeal®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Closure device for femoral artery access closure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Manual compression</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional manual compression</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FemoSeal®</intervention_name>
    <description>Closure device for femoral artery access closure</description>
    <arm_group_label>FemoSeal®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Manual compression</intervention_name>
    <description>Conventional manual compression</description>
    <arm_group_label>Manual compression</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must be at least 18 years old

          -  Patients undergoing femoral access coronary angiography

          -  Patient must be competent for providing informed, written consent

          -  Only 6F sheath

        Exclusion Criteria:

          -  Percutaneous coronary intervention

          -  Intra coronary measurements (FFR, IVUS, OCT, NIR)

          -  Groin hematoma before closure

          -  Pseudoaneurysm or AV fistula

          -  Significant stenosis of ilial or femoral artery

          -  Prior peripheral artery surgery

          -  INR &gt; 3,0

          -  Platelet count &lt; 120 million per millilitre blood

          -  Coagulopathy (bleeding disorder)

          -  Thrombolysis in the last 24h

          -  Planned heparin infusion after the procedure

          -  Pregnancy

          -  Uncontrolled hypertension &gt; 200 mmHg / 110 mmHg

          -  Femoral access device closure in the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels R. Holm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital Skejby</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital Skejby</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2009</study_first_submitted>
  <study_first_submitted_qc>October 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2009</study_first_posted>
  <last_update_submitted>September 5, 2013</last_update_submitted>
  <last_update_submitted_qc>September 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital Skejby</investigator_affiliation>
    <investigator_full_name>Niels Ramsing Holm</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>CAG</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

